^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Solid Tumor

    Related cancers:
    20h
    Nicotine Replacement Therapy Prescribing and Lung Cancer Screening in Hospitalized Patients (clinicaltrials.gov)
    P=N/A, N=220, Active, not recruiting, Medical University of South Carolina | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    20h
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    21h
    ENCORE: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, University of California, San Francisco | Not yet recruiting --> Recruiting
    Enrollment open
    21h
    AUSTRAL: Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (clinicaltrials.gov)
    P2, N=21, Recruiting, Mario Negri Institute for Pharmacological Research | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • ceralasertib (AZD6738)
    21h
    Toripalimab Combined With SBRT for NSCLC (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Loqtorzi (toripalimab-tpzi)
    21h
    Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    temozolomide
    22h
    GEICAM EMBARCAM: Registry Study of Pregnancy and Breast Cancer (clinicaltrials.gov)
    P=N/A, N=866, Active, not recruiting, Spanish Breast Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    22h
    FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT) (clinicaltrials.gov)
    P=N/A, N=11, Completed, Sunnybrook Health Sciences Centre | Recruiting --> Completed
    Trial completion
    22h
    CR108485: A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (clinicaltrials.gov)
    P1, N=114, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    onametostat (JNJ-64619178)
    22h
    Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    23h
    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Ascletis Pharmaceuticals Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    ASC61
    23h
    Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=4, Completed, Weill Medical College of Cornell University | Recruiting --> Completed
    Trial completion
    |
    FLT3 (Fms-related tyrosine kinase 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4)
    |
    Cabometyx (cabozantinib tablet)